Saturday, June 13, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 231 of 1,261
  1. US 11478510

    Chimeric antigen receptor and methods of use thereof

    The Regents of the University of California · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  2. US 11479794

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  3. US 11478425

    Extended release compositions comprising pyridostigmine

    Amneal Complex Products Research LLC · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  4. US 11479775

    RNA targeting of mutations via suppressor tRNAs and deaminases

    The Regents of the University of California · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  5. US 11479769

    Technique for treating cancer using structurally-reinforced S-TuD

    GeneDesign, Inc. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  6. US 11479774

    Methods of treating cancer harboring hemizygous loss of TP53

    The Board of Regents of the University of Texas System · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  7. US 11479771

    Antisense oligonucleotides for the treatment of eye disease

    ProQR Therapeutics II B.V. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  8. US 11479614

    Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptors

    AUTOLUS LIMITED · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  9. US 11479772

    Thiomorpholino oligonucleotides for the treatment of muscular dystrophy

    The Regents of the University of Colorado · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  10. US 11479617

    Chelator-functionalized glycosaminoglycans

    UNIVERSITY OF CONNECTICUT · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  11. US 11479595

    Methods for modulating an immune response

    Cue Biopharma, Inc. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  12. US 11479602

    Methods of treating C5-associated diseases comprising administering anti-C5 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  13. US 11479543

    Heterocyclic RIP1 kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  14. US 11479579

    Therapeutic compounds and methods

    Regents of the University of Minnesota · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  15. US 11479611

    HLA-G specific chimeric antigen receptor, nucleic acid, HLA-G specific chimeric antigen receptor expression plasmid, HLA-G specific chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer

    China Medical University Hospital · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  16. US 11479613

    Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins

    AUTOLUS LIMITED · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  17. US 11479576

    Nucleic acid prodrugs

    AVALO THERAPEUTICS, INC. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  18. US 11479556

    Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

    NURIX THERAPEUTICS, INC. · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  19. US 11478511

    Lymphocyte biomarkers for determining the clinical response to cell therapy

    Takeda Pharmaceutical Company Limited · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  20. US 11479560

    OX2R compounds

    The Board of Regents of the University of Texas System · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  21. US 11479545

    Compositions and methods for inhibiting phenyl triazole MLL1-WDR5 protein-protein interaction

    CHINA PHARMACEUTICAL UNIVERSITY · Granted Oct 25, 2022 · Expires Oct 20, 2042

    granted
  22. FR 3121841

    Traitement des hyperammoniémies

    BIOCODEX [FR] · Granted Oct 21, 2022 · Expires Oct 16, 2042

    granted
  23. US 11471442

    Administration of gut-selective JAK3 inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  24. US 11472808

    Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.